Lau et al. evaluated the use of MCP in hypertensive cardiac complications in a randomized controlled trial and found that inhibition of Gal-3 did not influence fibrosis cardiac biomarkers expression, but was slightly associated to a diminution of plasmatic creatinine and an increase of eGFR in MCP-treated patients. This evidence concerns the gene LGALS3 and complication.